Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

P2X4 Drives Sex-Specific Neuroprotection in Autoimmune Neuroinflammation

ABSTRACT: Microglia critically influence multiple sclerosis (MS) pathophysiology through debris clearance, myelin repair, and modulation of neuroinflammation. These processes are partly regulated by ATP-gated ion channel P2X4, predominantly expressed in microglia. We previously reported that ivermectin (IVM), a positive allosteric modulator of P2X4, promotes myelin phagocytosis, remyelination, and functional recovery in experimental autoimmune encephalomyelitis (EAE). Here, we dissected the cellular basis of P2X4-mediated effects using P2X4mCherryIN knock-in (P2X4KI) mice, in which P2X4 is replaced by a non-internalized variant (P2X4KI), leading to increased surface localization at the plasma membrane. Constitutive and myeloid-specific P2X4KI (Cd11b-P2X4KI) mice showed significant amelioration of EAE motor deficits, although exclusively in females. Despite equivalent P2X4 expression, function, and IVM responsiveness between sexes, progesterone potentiated P2X4 currents and prolonged channel deactivation, revealing direct hormonal modulation of P2X4 gating. Notably, ovariectomy abolished P2X4-mediated protection in females, confirming the requirement of female hormones. These findings identify microglial P2X4 as a critical modulator of neuroinflammatory outcomes and uncover a previously unrecognized hormone–P2X4 interaction that underlies sex-specific disease modulation. Targeting this pathway may enable precision therapies for MS.

ORGANISM(S): Mus musculus

PROVIDER: GSE324320 | GEO | 2026/03/14

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Deletion of the X gene, Kdm6a, in microglia reverses the disease-associated microglia transcriptome

Project description:Multiple sclerosis (MS) exhibits a sex difference with the female to male bias nearly 3:1. This may be due to differences in sex hormones, sex chromosomes, or both. Kdm6a is an X chromosome gene that escapes X-inactivation and encodes for a histone demethylase which can modulate autosomal gene expression. Females have two copies of Kdm6a, while males have one copy. Microglia play a key role in the neuropathology of MS. Thus, Kdm6a was selectively deleted in microglia in the MS model, experimental autoimmune encephalomyelitis (EAE), to determine the effect on microglia, neuropathology, and clinical disease. Deletion of the X chromosome gene Kdm6a in microglia ameliorated EAE in females. The transcriptome in microglia Kdm6a knockout mice compared to wild type showed downregulation of disease-associated microglia (DAM) markers and upregulation of resting microglia markers. Gene ontology analyses demonstrated that selective deletion of Kdm6a in microglia caused reversal of the transcriptome changes induced by EAE. In contrast to effects in female mice, selective deletion of Kdm6a in microglia of male mice had no effect on EAE. To complement findings using genetic knockouts, pharmacologic blocking of Kdm6a was done using metformin. Metformin treatment, compared to vehicle, ameliorated EAE in females, with microglia histologically and transcriptionally similar to those from healthy controls. Further in translation, analyses of microglia transcriptomes in MS and healthy controls suggested that blocking Kdm6a may be a novel strategy to target disease-associated microglia in MS women.

2025-10-15 | GSE297367 | GEO

Deletion of the X gene, Kdm6a, in microglia reverses the disease-associated microglia transcriptome [CUT&Run]

2025-10-15 | GSE297450 | GEO

Deletion of the X chromosome gene Kdm6a in microglia is protective in the multiple sclerosis model [hippocampus]

Project description:Multiple sclerosis (MS) exhibits a sex difference in susceptibility with females affected more frequently than males. Sexual dimorphisms may be due to differences in sex hormones, sex chromosomes, or both. Regarding sex chromosomes, some X chromosome genes escape X-inactivation and have higher expression in females (XX) compared to males (XY). The Genotype Tissue Expression Project (GTEx) has found that 37% of all genes exhibit sex biased expression which is tissue-specific and cell-specific, but the etiology and ramifications of this sex difference remain unknown. Kdm6a is an X chromosome gene that escapes X-inactivation and encodes for a histone demethylase which can modulate autosomal gene expression. Given the important role of microglia in neurodegenerative diseases, we created a tissue-specific and cell-specific conditional knock out (cKO) of Kdm6a in microglia and induced experimental autoimmune encephalomyelitis (EAE), the most widely used mouse model for MS. Deletion of Kdm6a in microglia ameliorated EAE. Gene expression analysis of spinal cord microglia during EAE in the Kdm6a cKO revealed downregulation of degeneration associated microglial markers and upregulation of resting microglial markers compared to EAE in wild type. Genome wide transcriptome analyses demonstrated reversal of the EAE associated transcriptome in microglia in Kdm6a cKO mice, instead aligning with that of the transcriptome of microglia in healthy mice. Finally, there was a sex difference in the effect of selective deletion of Kdm6a in microglia whereby EAE was abrogated in females more significantly than in males. Together, this demonstrates that the X-escapee Kdm6a is disease promoting in microglia of females with neurodegenerative disease.

2025-10-15 | GSE221400 | GEO

Deletion of the X chromosome gene Kdm6a in microglia is protective in the multiple sclerosis model, female and male II

2025-10-15 | GSE261726 | GEO

Deletion of the X chromosome gene Kdm6a in microglia is protective in the multiple sclerosis model, female and male

2025-10-15 | GSE246008 | GEO

Deletion of the X chromosome gene Kdm6a in microglia is protective in the multiple sclerosis model

2025-10-15 | GSE220566 | GEO

Harnessing microglia capacity to facilitate myelin regeneration in chronically demyelinated brain lesions

Project description:Failure in remyelination is a key feature of progressive multiple sclerosis (MS) that drive neurodegeneration and accumulation of disabilities. Microglia crucially facilitate oligodendrocyte remyelination in MS lesions through myelin phagocytosis, and subsequent cholesterol metabolism and release. However, microglia lose this capacity in chronic demyelinated lesions, as they acquire a dysfunctional phenotype characterized by intracellular accumulation of lipid droplets due to impaired cholesterol processing of myelin debris. Given the abundance of microglia in chronic MS lesions, revitalizing their pro-remyelination capacity represents a critical repair strategy for progressive MS. Here, we reveal that dysregulation of neuregulin-1 underlies impaired remyelination in chronically demyelinated brain lesions. Therapeutic restoration of neuregulin-1 supports remarkable myelin regeneration by augmenting microglia capacity for clearance of myelin debris, cholesterol metabolism and efflux. Altogether, we demonstrate the promise of neuregulin-1 as an endogenous target to facilitate microglia reparative functions in progressive MS in which there is an unmet critical need for new treatments.

2026-03-09 | GSE282653 | GEO

Transcriptional profiling of human microglia reveals grey-white matter heterogeneity and multiple sclerosis-associated changes

Project description:Microglia are brain-resident, myelin-phagocytosing cells, yet their role in lesion initiation in grey and white matter regions in multiple sclerosis (MS) is unclear. We isolated primary microglia from both, occipital cortex and corpus callosum, of 10 MS and 11 control donors and studied their transcriptional profile by RNA sequencing, thereby identifying regional and MS-associated changes. Identification of pathways underlying regional differences showed a relatively increased type I interferon response in cortical grey matter microglia, while white matter microglia more highly expressed NF-κB pathway genes. In normal-appearing white matter MS tissue, lipid metabolism genes were increased, suggesting processing of myelin by microglia already in areas seemingly devoid of MS pathology. Normal-appearing grey matter MS microglia showed increased activation of glycolysis and metal ion homeostasis, possibly reflecting microglia reacting to iron depositions. Notably, expression of genes associated with microglia homeostasis were hardly changed, suggesting that subtle regional changes in MS-associated microglia do not yet affect their resting state.

2019-03-13 | GSE111972 | GEO

MOG-encoding DNA vaccines ameliorate EAE and display neuroprotective effects in treated mice summary

Project description:Vaccination with naked DNA encoding myelin basic protein represents a promising therapeutic strategy in multiple sclerosis (MS). In this study, we assessed the potential of vaccination with a DNA construct coding for the myelin oligodendrocyte glycoprotein (MOG), an important candidate autoantigen in MS, to induce tolerance and protect against experimental autoimmune encephalomyelitis (EAE). Herein, we demonstrated that MOG-DNA vaccination reduced the clinical and histopathological signs of EAE when administered in both prophylactic and therapeutic settings. Further mechanistic experiments revealed that the protective effects of MOG-DNA vaccines were associated with a reduction of antigen-specific Th1 and Th17 cellular immune responses and expansion of regulatory T cells in periphery, and up-regulation in the central nervous system of genes encoding neurotrophic factors and proteins involved in remyelination. These results may set the rationale for the use of MOG-based DNA vaccines to induce tolerance in MS patients. We analyzed brain and spinal cord samples from five treated and five control mice

2011-07-08 | E-GEOD-30482 | biostudies-arrayexpress

Maresin-1 promotes neuroprotection in relapsing remitting mouse model of multiple sclerosis

Project description:Multiple sclerosis (MS) is a prevalent inflammatory neurodegenerative disease in young people, causing neurological abnormalities and impairment. We investigated the effect of maresin 1 (MaR1) on the progression of disease in relapsing remitting form of experimental autoimmune encephalomyelitis (RR-EAE). Treatment with MaR1 in RR-EAE accelerated inflammation resolution, protected against neurological impairments, and delayed disease development by reducing immune cell infiltration (CD4+IL17+ and CD4+IFNg+) into the CNS. Furthermore, injection of MaR1 enhanced IL-10 production, primarily in macrophages and CD4+ cells. However, neutralizing IL-10 with an anti-IL-10 antibody eliminated MaR1's protective impact on RR-EAE, implying that IL-10 plays a role in MaR1's EAE protection. Metabolism is increasingly being recognized as a critical element controlling the effector activity of many immune cells. Our investigation found that, when compared to vehicle treatment, MaR1 administration significantly repaired the metabolic dysregulation seen in CD4+ cells, macrophages, and microglia in the treated group. Furthermore, MaR1 treatment restored defective efferocytosis in EAE mice, which was potentially facilitated by the induction of metabolic alterations in macrophages and microglia. MaR1 also preserved myelin in the EAE group and regulated O4+ oligodendrocyte metabolism by reversing metabolic dysregulation via increased mitochondrial activity and decreased glycolysis. Overall, in a preclinical MS animal model, MaR1 therapy has anti-inflammatory and neuroprotective properties. It also induced metabolic reprogramming in disease-associated cell types, increased efferocytosis, and maintained myelination. These findings suggest MaR1's potential as a novel therapeutic agent for MS and other autoimmune diseases

2024-12-08 | GSE276812 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data